Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP cut its position in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 30.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,544 shares of the company's stock after selling 5,596 shares during the period. Bridgewater Associates LP's holdings in Guardant Health were worth $383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of GH. R Squared Ltd purchased a new stake in Guardant Health during the fourth quarter worth about $26,000. SBI Securities Co. Ltd. acquired a new stake in shares of Guardant Health during the fourth quarter worth $43,000. Kimelman & Baird LLC acquired a new position in Guardant Health during the 4th quarter valued at about $58,000. Quantbot Technologies LP bought a new position in Guardant Health in the 4th quarter valued at about $80,000. Finally, Jones Financial Companies Lllp boosted its stake in Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Guardant Health Price Performance

Shares of GH stock traded up $0.24 during trading hours on Friday, reaching $47.65. 461,929 shares of the company traded hands, compared to its average volume of 2,264,479. The company has a market cap of $5.88 billion, a P/E ratio of -13.38 and a beta of 1.45. Guardant Health, Inc. has a 12-month low of $16.77 and a 12-month high of $50.89. The firm has a 50-day moving average price of $43.37 and a 200 day moving average price of $37.00.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. The company had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Sell-side analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. JPMorgan Chase & Co. increased their price objective on Guardant Health from $50.00 to $55.00 and gave the stock an "overweight" rating in a report on Friday, February 21st. Morgan Stanley lifted their price objective on Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. Barclays dropped their price target on Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. Stifel Nicolaus increased their price target on shares of Guardant Health from $45.00 to $53.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Piper Sandler boosted their price objective on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Twenty research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $49.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.